{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:34:25Z","timestamp":1793522065964,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Defense Prostate Cancer Research Program","award":["W81XWH-18-1-0363"],"award-info":[{"award-number":["W81XWH-18-1-0363"]}]},{"name":"National Cancer Institute","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Astra Zeneca","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous recombination repair (HRR) gene alterations. Combination approaches may expand activity beyond HRR-altered disease. We conducted a phase 2 study of the PARP inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castration-resistant prostate cancer (mCRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-arm, open-label phase 2 trial of olaparib plus durvalumab in men with mCRPC previously treated with abiraterone and\/or enzalutamide. Pretreatment biopsies of metastatic lesions were attempted for tumor sequencing. Peripheral blood was collected longitudinally for immune profiling of cell subsets and soluble factors, circulating tumor DNA (ctDNA) analyses, and peripheral blood mononuclear cell (PBMC) gene expression profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      61 patients were enrolled; 60 were evaluable. Median age was 65 years (45\u201388). Median radiographic progression-free survival (rPFS) was 5.0 months (95% CI 4.6 to 7.6)\u2009and median overall survival (OS) was 19.1 months (95% CI 15.0 to 29.3 months). 10 patients achieved partial responses, and 17 (28%) had \u226550%\u2009prostate-specific antigen declines. Patients with\n                      <jats:italic>BRCA2<\/jats:italic>\n                      variants experienced longer rPFS (13.2 months; 95% CI 7.7 to 20.2 months) than patients without\n                      <jats:italic>BRCA2<\/jats:italic>\n                      variants (4.8 months; 95% CI 4.5 to 6.4 months, p=0.0026). Baseline ctDNA fraction was higher in patients with radiographic progression than in those with partial response (p=0.022) and inversely correlated with time-to-progression (\u03c1=\u22120.51). Treatment- induced early peripheral immune perturbations included transient inflammatory cytokine increases and expansion of activated\/proliferating T cells with concurrent regulatory features. Exploratory PBMC profiling identified\n                      <jats:italic>IL1R2<\/jats:italic>\n                      as a response-associated transcript, and lower\n                      <jats:italic>IL1R2<\/jats:italic>\n                      expression was associated with longer OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Olaparib plus durvalumab demonstrated modest activity in HRR-unselected mCRPC, with clinical benefit enriched in\n                      <jats:italic>BRCA2<\/jats:italic>\n                      -variant disease. Integrated ctDNA and peripheral immune analyses support ongoing efforts to refine molecular and immune selection strategies and to better define mechanisms of benefit and resistance for combination approaches in mCRPC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02484404\">NCT02484404<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014365","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:50:15Z","timestamp":1774450215000},"page":"e014365","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02484404","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00034216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02484404","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chennan","family":"Li","sequence":"first","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahoko","family":"Sato","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanny B","family":"Aragon-Ching","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghali","family":"Goswami","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-3073","authenticated-orcid":false,"given":"Renee N","family":"Donahue","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-4084","authenticated-orcid":false,"given":"Lisa M","family":"Cordes","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Baj","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C Y","family":"Seo","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T","family":"Terrigino","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Bright","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Thomas","family":"Hennigan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaiah M","family":"King","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana Y","family":"Trostel","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Fenimore","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A","family":"Calzone","sequence":"additional","affiliation":[{"name":"Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-4072","authenticated-orcid":false,"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L","family":"Dahut","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Figg","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G","family":"Sowalsky","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-1332","authenticated-orcid":false,"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026032507500495000_14.3.e014365.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026032507500495000_14.3.e014365.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"2026032507500495000_14.3.e014365.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"2026032507500495000_14.3.e014365.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"2026032507500495000_14.3.e014365.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"2026032507500495000_14.3.e014365.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"2026032507500495000_14.3.e014365.7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"The Lancet"},{"key":"2026032507500495000_14.3.e014365.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026032507500495000_14.3.e014365.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026032507500495000_14.3.e014365.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.01.020"},{"key":"2026032507500495000_14.3.e014365.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"2026032507500495000_14.3.e014365.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"2026032507500495000_14.3.e014365.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"},{"key":"2026032507500495000_14.3.e014365.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"2026032507500495000_14.3.e014365.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"2026032507500495000_14.3.e014365.16","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2020-0697"},{"key":"2026032507500495000_14.3.e014365.17","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026032507500495000_14.3.e014365.18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA17","article-title":"TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Agarwal","year":"2023","journal-title":"JCO"},{"key":"2026032507500495000_14.3.e014365.19","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"2026032507500495000_14.3.e014365.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"2026032507500495000_14.3.e014365.21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061420","article-title":"PARP Inhibitors Resistance: Mechanisms and Perspectives","volume":"14","author":"Giudice","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026032507500495000_14.3.e014365.22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.trecan.2019.06.004","article-title":"Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer","volume":"5","author":"Lee","year":"2019","journal-title":"Trends Cancer"},{"key":"2026032507500495000_14.3.e014365.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003"},{"key":"2026032507500495000_14.3.e014365.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"2026032507500495000_14.3.e014365.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"2026032507500495000_14.3.e014365.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"2026032507500495000_14.3.e014365.27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00233"},{"key":"2026032507500495000_14.3.e014365.28","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026032507500495000_14.3.e014365.29","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women\u2019s Cancers: A Dose-Escalation, Phase I Study","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026032507500495000_14.3.e014365.30","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"2026032507500495000_14.3.e014365.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2026032507500495000_14.3.e014365.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02031"},{"key":"2026032507500495000_14.3.e014365.33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0937"},{"key":"2026032507500495000_14.3.e014365.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2026032507500495000_14.3.e014365.35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","article-title":"Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study","volume":"36","author":"Graff","year":"2025","journal-title":"Ann Oncol"},{"key":"2026032507500495000_14.3.e014365.36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b\/2 KEYNOTE-365 Cohort A Study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"},{"key":"2026032507500495000_14.3.e014365.37","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT145","article-title":"Abstract CT145: Olaparib +\/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial","volume":"83","author":"Fanucci","year":"2023","journal-title":"Cancer Res"},{"key":"2026032507500495000_14.3.e014365.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1010"},{"key":"2026032507500495000_14.3.e014365.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01652"},{"key":"2026032507500495000_14.3.e014365.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37736-3","article-title":"Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer","volume":"13","author":"Inomata","year":"2023","journal-title":"Sci Rep"},{"key":"2026032507500495000_14.3.e014365.41","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910293","article-title":"Functional systemic CD4 immunity is required for clinical responses to PD-L1\/PD-1 blockade therapy","volume":"11","author":"Zuazo","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2026032507500495000_14.3.e014365.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"key":"2026032507500495000_14.3.e014365.43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4466"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:50:18Z","timestamp":1774450218000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-014365"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014365","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}